PMFA
RNTX

Plante Moran Financial Advisors’s Rein Therapeutics RNTX Stock Holding History

Plante Moran Financial Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15
Closed -$3K – 877
2017
Q2 		$3K Buy
+15
New +$3.29K ﹤0.01% 728

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

Plante Moran Financial Advisors's RNTX Position: Q3 2017 in Review

Plante Moran Financial Advisors sold out of Rein Therapeutics (RNTX) in Q3 2017, closing a stake of 15 shares — an estimated $3K sold.

Plante Moran Financial Advisors first reported a position in RNTX in Q2 2017 and held it in 1 quarter. The position peaked at $3K in Q2 2017. 31 funds tracked by Wall St. Rank hold RNTX as of Q3 2017.

  • Plante Moran Financial Advisors reported no remaining Rein Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Plante Moran Financial Advisors sold 15 Rein Therapeutics shares in Q3 2017, an estimated $3K.
  • Plante Moran Financial Advisors first reported a position in Rein Therapeutics in Q2 2017 and held it in 1 quarter.
  • Plante Moran Financial Advisors's Rein Therapeutics position peaked at $3K in Q2 2017.
  • 31 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2017.

Based on Plante Moran Financial Advisors's 13F filing for Q3 2017, filed 8 Nov 2017.